A 5-Step Framework That Turns Biotech Speculation Into Discipline

Speculation is not gambling — the difference is process

A biotech stock with no revenue is not an "investment." It is a speculation. The difference is not vocabulary, it is sizing and procedure. Gambling sets the size by gut feel. Speculation sets the size by framework.

Here is the five-step framework I actually used to evaluate the three psychedelic names in the comparison piece. It transfers cleanly to any pre-revenue innovation name — quantum computing, fusion, gene therapy.

1. Gross margin — how much sticks per dollar of revenue

The Wall Street name for this is gross margin. Of every dollar of revenue, how much remains after the cost of manufacturing the drug.

• Above 70%: the baseline for a real, patent-protected drug company. J&J's Spravato sits in this range.
• Below 50%: warning sign. Either pricing pressure or manufacturing inefficiency.
• No revenue yet: not measurable. → proceed to the next filter but cut position size further.

Compass, atai, and GH Research all carry "undetermined" on this filter today. That single fact materially shrinks any reasonable position.

2. How many years of patent runway are left

Patents are the only moat that holds a drug's price. The day a patent expires, generics enter and pricing collapses 80-90% almost overnight.

• Under 5 years: too short. Patent expiry hits before revenue ramps fully.
• 15+ years: strong. Allows commercial ramp and price retention to compound.
• Multiple patents (formulation, dosing protocol, manufacturing): Compass is structured this way. Losing one claim does not collapse the moat.

Caveat: "has patents" and "survives litigation" are different statements. You only learn the truth when a competitor sues.

3. Are they already selling something

I prefer companies with revenue. Clinical trials can vanish in a single FDA decision. Revenue is not a single binary event.

• In market: ideal. Trend analysis becomes available.
• Phase 3 completed, approval imminent: mid-tier. Suitable for catalyst bets but carries rejection risk.
• Phase 1-2: highest risk. Clinical success probabilities drop with each earlier stage.

All three psychedelic names fail this filter — none have revenue. That is precisely why the position is sized as a category bet, not a fundamentals bet.

4. Position size — the 1-3% rule

A pre-revenue biotech category should not exceed 1-3% of portfolio, in aggregate, not per stock.

Why 1-3%:

• If a 10x prints, 1-3% becomes 10-30% → mandatory profit taking
• If it goes to zero, 1-3% disappears → retirement timing unchanged
• A 50-80% drawdown is absorbed by the other 97-99%

The core property of this rule is asymmetric: being wrong does not change your life, being right does.

5. Exit discipline — buy-and-forget is the most dangerous default

Biotech innovation names do not reward buy-and-hold-forever. The recurring pattern looks like this:

1. IPO hype phase, parabolic spike (Compass at ~$60)
2. Expectations miss, 90% drawdown (Compass into single digits)
3. Years of sideways grinding
4. Real catalyst, re-rate higher — this is the actual entry zone
5. New hype phase

In my own portfolio I bought J&J in late 2025, took roughly 45% gains, and sold. I do not stay married to a single stock — I follow the money flow, not the ticker.

The framework, compressed

Biotech speculation collapses into a few rules:

• If revenue exists → look at margins and patents
• If no revenue → it is a catalyst bet, sized by category
• Position size stays small regardless
• Discipline at the exit matters as much as discipline at the entry

Follow these five and a single wrong bet does not delay retirement. Simultaneously, a single right bet can generate a meaningful outcome.